Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

In Robert F. Kennedy Jr.’s first interview as secretary of the Department of Health and Human Services, he made multiple ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

After several trials, the FDA approved the first GLP-1 medication for weight loss in 2021, branded as Wegovy. Dr. Shweta Akhouri is a board-certified family and obesity medicine physician.

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.

The FDA tells Yahoo Life that it is aware of the complaints. In the meantime, the Obesity Society urges consumers “to speak with their medical doctor regarding obesity medications,” according ...